Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based EMD Millipore and Japan-based Sysmex have announced a clinical research, licensing and joint development agreement, in which Sysmex will use EMD Millipore’s flow cytometry technology as a platform to accelerate the creation of more powerful diagnostic tools for research in blood disorders.
Subscribe to our email newsletter
If successful, both companies will collaborate on developing the imaging flow technology platform for future commercialization in hematology.
Currently, Sysmex is conducting a clinical study assessing EMD Millipore’s Amnis imaging flow cytometry technology for hematologic disorders such as leukemia.
After completing the research, Sysmex and EMD Millipore plan to combine the imaging flow cytometry technology with Sysmex’s technologies to develop new imaging flow cytometry technology that will generate image data of molecular (protein) expression status, as well as the identification of abnormal cells in the blood.
Sysmex is likely to promote the creation of new diagnostic technologies, which will lead to the realization of personalized medicine and contribute to the advancement of healthcare by meeting increasingly diverse and sophisticated testing needs.
In the EMD Millipore-Sysmex collaboration, the companies will firstly conduct a clinical trial of the Amnis technology using patient blood samples for detecting and characterize leukemic conditions and other hematologic disorders. Previously, a joint feasibility study demonstrated very encouraging results.
EMD Millipore division president Robert Yates noted the company’s Amnis imaging flow cytometry has the potential to transform hematologic research and diagnostics.
"We believe this agreement will lead to improved care for patients around the world," Yates added.